Navigation Links
Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020
Date:7/21/2014

PORTLAND, Oregon, July 21, 2014 /PRNewswire/ --


A new report by Allied Market Research titled, "Global biosimilars/follow-on-biologics market (types, applications and geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", suggests that the global biosimilars market would reach $35 billion by 2020 from the estimated $1.3 billion in 2013. Deeper penetration with clearer regulatory pathways in developed markets and higher efficacy & safety in emerging markets will back the market growth during the forecast period.

Over 10 blockbuster biologics with annual sales of $60 billion are facing patent expiries in Europe and in the U.S. during the next four years. Top pharmaceutical manufacturing brands are repositioning their strategic agendas from approvals to product launches to gain market capitalization. "Biosimilars developers have been using emerging markets with less intellectual property protection as their launch pad for established markets" say AMR analysts. "With regulatory framework maturing in established markets, it will be easier for biosimilars manufacturers to quickly enter into such markets" analysts added, citing collaboration between Mylan and Biocon to commercialize biosimilar of trastuzumab in India and the approval of first biosimilar version of monoclonal antibody drug by Hospira in Europe. Due to lower intellectual property rights protection and higher activity of regional players, the Asia Pacific region has emerged as the leader in biosimilars market.

Browse the report with TOC at http://www.alliedmarketresearch.com/biosimilars-market

Biosimilars as a cost effective alternative provides room for economical biopharmaceutical medications for chronic disorders that are rampant around the globe. The widespread chronic disorders and the need for cost effective medication is driving the biosimilars commercialization. The strategic collaborations for global expansion, especially for the high potential segments such as monoclonal antibodies (mAbs) and erythropoietin will be key to the market growth; however, the strategies are persistently threatened by traditional patent-infringements. Key product segments such as follitropins, interferons, and insulin biosimilars will emerge lucrative segments in the long run. Certain therapeutic classes such as oncology and autoimmune diseases will gain importance from the biosimilars developers as these classes will have higher room for growth due to awaited patent expiries during 2014 - 2019.

See Global Lung Cancer Therapeutics Market report at http://www.alliedmarketresearch.com/lung-cancer-therapeutics-market

AMR analysis suggests that Erythropoietin biosimilars are the most promising products, anticipating substantial revenue generation from patented biologics. Granulocyte colony-stimulating factor biosimilars are following erythropoietin in terms of revenue generation during the forecast period. Biosimilars in oncology disorders are currently dominating the market due to high-priced patented drugs such as erythropoietin and monoclonal antibodies that are largely used in the oncology treatments. However, biosimilars for chronic and autoimmune diseases and blood disorders are the fastest growing applications and expecting a salutary growth during the analysis period.

See all pharmaceuticals market reports at http://www.alliedmarketresearch.com/pharmaceuticals-market-report

Key biosimilars developers such as Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc. and Genentech (Roche Group) have adopted approval and clinical trials as key developmental strategies to gain competitive edge in the pharmaceuticals market. These firms are also focusing on adhering to regulatory guidelines to expand in the world markets.

About Us: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Sona Padman
5320 SW Macadam Avenue,
Suite 100, Portland, OR 97239
United States
Direct:    +1-(617)-674-4143
Toll Free: +1-(855)-711-1555 (U.S. & Canada)
Fax: +1-(855)-550-5975
Web: http://www.alliedmarketresearch.com/



'/>"/>
SOURCE Allied Market Research
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research
2. Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo
3. Optimizing Market Research to Best Serve Internal Customers
4. Hanger to Release Second Quarter 2014 Results on Tuesday, August 5 After Market Close and Host Conference Call at 9:00 am Eastern on Wednesday, August 6
5. Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis
6. Global Physical Vapor Deposition Market is Expected to Reach USD 20.45 Billion by 2019: Transparency Market Research
7. Dengue Vaccine Market Worth $400 million with 42% CAGR 2015 to 2020
8. Global NewBorn Screening (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter) Market - Forecast to 2019
9. Defibrillators Market (Advanced Life Support, Automated External Defibrillators, Implantable Cardioverter Defibrillators, Wearable Defibrillators) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
10. Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth,
11. X-Ray Equipment Markets in the World to 2018 - Market Size, Trends, and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):